Healthcare Technology Company Announces Positive Clinical Update From Cancer Trial
Lantern Pharma Announces Positive Clinical Update from Phase 2 HARMONIC™ Clinical Trial.
Disclaimer: The following article provides an overview of the clinical update announced by Lantern Pharma regarding their ongoing Phase 2 HARMONIC™ clinical trial for never smokers with advanced non-small cell lung cancer (NSCLC). The content herein is intended for informational purposes only and does not constitute medical advice or promotional material. Always consult with a qualified healthcare provider for medical advice and treatment options.
Real-time information is available daily at https://stockregion.net
Lantern Pharma, a company specializing in the use of artificial intelligence (AI) for the development of cancer therapies, has recently shared promising preliminary results from its ongoing Phase 2 HARMONIC™ clinical trial. This study focuses on never smokers with advanced NSCLC, specifically lung adenocarcinoma, who have developed resistance to tyrosine kinase inhibitors (TKIs). The aim of the trial is to enhance patient outcomes through the combination of LP-300 and standard-of-care chemotherapy.
Study Design and Objectives
The HARMONIC™ Phase 2 study is designed to address a gap in the treatment of never smokers with advanced NSCLC. Unlike traditional smokers, these patients often present driver mutations that lead to resistance against TKI treatments. The primary objective of the study is to assess the efficacy and safety of LP-300 when used in conjunction with pemetrexed and carboplatin chemotherapy. In the lead-in cohort of the Phase 2 trial, seven patients were enrolled to receive LP-300 along with the chemotherapy agents pemetrexed and carboplatin. The administration of these drugs was carried out intravenously, ensuring that each patient received the combination therapy as planned. The initial results from the lead-in cohort are encouraging. Out of the seven patients, six demonstrated clinical benefits from the combination therapy:
Partial Responses: Three patients exhibited partial responses, with an average tumor size reduction of 51%.
Stable Disease: Another three patients maintained stable disease, showing an average tumor size reduction of 13%.
This data translates to a clinical benefit rate and disease control rate of 86% for the initial cohort, with an objective response rate (ORR) of 43%. A preliminary analysis of the safety lead-in data reveals no new safety concerns associated with the combination therapy. No dose-limiting toxicities (DLTs) or treatment-related serious adverse events (SAEs) were observed. The most common adverse events reported were decreases in white blood cell count and platelet count (thrombocytopenia).
Efficacy Across Demographics and Prior Treatments
The early efficacy results are noteworthy, showing positive outcomes irrespective of prior TKI treatments, patient demographics, and metastatic disease sites. Notably, patients with low to intermediate tumor mutation burden (TMB) responded positively to the LP-300 and chemotherapy regimen.
Currently, there are no approved therapies specifically targeting NSCLC in never smokers, which represents a growing patient demographic worldwide. The lack of dedicated treatments reveals the significance of the HARMONIC™ trial and the potential impact of LP-300 in this niche but critical area of oncology. Lantern Pharma leverages its proprietary AI platform, RADR®, to accelerate drug discovery and development. RADR® supports the identification and validation of drug mechanisms and helps uncover insights within targeted patient populations. With over 100 billion data points, this platform plays a crucial role in advancing both Lantern’s portfolio and collaborative initiatives.
Lantern Pharma's Phase 2 HARMONIC™ clinical trial presents promising preliminary results for never smokers with advanced NSCLC. The combination of LP-300 and standard-of-care chemotherapy demonstrates a high clinical benefit rate, manageable safety profile, and potential efficacy across various patient subgroups. These findings offer hope for a patient population that currently lacks specific therapeutic options.
Disclaimer: The information provided in this article is based on preliminary clinical data and should not be interpreted as conclusive evidence or medical advice. For personal health concerns and treatment options, individuals are encouraged to consult with a healthcare professional.
Real-time information is available daily at https://stockregion.net